California-based medical device maker Volcano (NSDQ:VOLC) won U.S. and European regulatory approvals to market its latest Visions PV 0.35 device, a digital intravascular ultrasound catheter designed for large vessels.

The new Visions PV device can image diseased arteries and veins and help physicians make real-time measurements while requiring less contrasting agents during the procedure, according to a press release.

The IVUS catheter facilitates less invasive vessel treatment and repair that may be preferable to open surgery, potentially lowering recovery times and post-procedure complications in certain patients, according to Volcano.

"Precise device sizing and placement is critical for positive outcomes," chief operations officer and IV imaging unit leader David Sheehan said in prepared remarks. "Volcano believes IVUS can play an important role in guiding endovascular and other peripheral therapies."

The San Diego-based precision-guided therapy tools maker recently announced a partnership with medtech titan Medtronic (NYSE:MDT), through which the companies combined the product portfolios to form budget-friendly hospital contracts for devices targeting coronary artery disease.

Those product bundles will include Medtronic’s suite of guide-wires, balloon catheters and stents as well as Volcano’s intravascular ultrasound imaging technology and functional management tools.

VOLC shares slid 1.3% this morning, trading at $28.07 as of about 11 a.m.